WEBVTT - Mike Doustdar Talks Strong Demand for Weight Loss Pills

0:00:02.480 --> 0:00:07.000
<v Speaker 1>Bloomberg Audio Studios, podcasts, radio news.

0:00:07.880 --> 0:00:10.200
<v Speaker 2>So we spoke in December after you were granted US

0:00:10.200 --> 0:00:13.560
<v Speaker 2>approval to launch your OBC pill this month in January,

0:00:13.640 --> 0:00:16.239
<v Speaker 2>the first drugmaker to do so. I know it's early,

0:00:16.280 --> 0:00:18.040
<v Speaker 2>but what has uptake looked like so far?

0:00:18.360 --> 0:00:20.800
<v Speaker 1>It's been really exciting to launch, and I think when

0:00:20.840 --> 0:00:24.640
<v Speaker 1>you go around this congress and hear the excitement externally

0:00:24.760 --> 0:00:27.680
<v Speaker 1>we are of course objective, but externally everyone being excited

0:00:27.680 --> 0:00:30.840
<v Speaker 1>about it gives you a good feeling. The uptake has

0:00:30.880 --> 0:00:32.800
<v Speaker 1>been good, but it's really early days for me to

0:00:32.800 --> 0:00:36.360
<v Speaker 1>go into the details of it, but it really speaks

0:00:36.400 --> 0:00:39.200
<v Speaker 1>to the fact that we also spoke earlier. There's been

0:00:39.280 --> 0:00:42.200
<v Speaker 1>a lot of people that are excited about GOP one

0:00:42.240 --> 0:00:46.600
<v Speaker 1>category weight loss, but did not want to take an injection.

0:00:47.159 --> 0:00:51.319
<v Speaker 1>There's a taboo of injection, there's needle phobia, and they've

0:00:51.360 --> 0:00:55.600
<v Speaker 1>been waiting. So we are super excited that we're finally

0:00:55.680 --> 0:00:58.880
<v Speaker 1>having an offering for this large group of people that

0:00:59.040 --> 0:00:59.960
<v Speaker 1>have been wanting a pill.

0:01:00.400 --> 0:01:02.560
<v Speaker 2>And critically, you have a couple months here when it

0:01:02.600 --> 0:01:05.720
<v Speaker 2>comes to Eli Lily, they're slated to get approval sometime

0:01:05.840 --> 0:01:08.800
<v Speaker 2>in the next couple months. How do you prevent your

0:01:08.840 --> 0:01:12.080
<v Speaker 2>patients from switching to Lily's pill, which I understand doesn't

0:01:12.120 --> 0:01:15.280
<v Speaker 2>have exactly the same food restrictions as yours does. Once

0:01:15.400 --> 0:01:16.400
<v Speaker 2>that is on the market.

0:01:16.920 --> 0:01:20.160
<v Speaker 1>A couple of points, when we started actually deciding how

0:01:20.240 --> 0:01:22.920
<v Speaker 1>to go into the oral segment and decided that we

0:01:22.920 --> 0:01:27.240
<v Speaker 1>should put our protein and peptide encapsulate it and take

0:01:27.280 --> 0:01:29.400
<v Speaker 1>that route, most people thought that this is going to

0:01:29.440 --> 0:01:33.320
<v Speaker 1>be impossible. Scientifically, you don't find examples of the protein

0:01:33.440 --> 0:01:38.640
<v Speaker 1>large protein peptides going inside orally and not being dissolved

0:01:38.640 --> 0:01:42.080
<v Speaker 1>by the enzymes of your stomach. We were able to

0:01:42.120 --> 0:01:44.880
<v Speaker 1>do that magically, I would say, But now, of course

0:01:44.880 --> 0:01:47.720
<v Speaker 1>we're getting the fruits of that. We have for the

0:01:47.760 --> 0:01:51.680
<v Speaker 1>first time the efficacy of our pill at sixteen point

0:01:51.760 --> 0:01:56.640
<v Speaker 1>six percent when you take the drug being exactly equal

0:01:56.960 --> 0:01:59.240
<v Speaker 1>to the pen version of it, the vigo vi pen

0:01:59.680 --> 0:02:02.880
<v Speaker 1>again at sixteen point six percent, That of course is

0:02:02.920 --> 0:02:04.520
<v Speaker 1>second to none. When you take a look at the

0:02:04.600 --> 0:02:09.120
<v Speaker 1>data from all of our competition in late pipeline or

0:02:09.160 --> 0:02:12.200
<v Speaker 1>early pipeline, no one has that efficacy. That I think

0:02:12.280 --> 0:02:14.360
<v Speaker 1>is a big leap that we will talk to. Not

0:02:14.560 --> 0:02:17.800
<v Speaker 1>least of course VGOVI pill also have the CV benefits

0:02:18.160 --> 0:02:20.919
<v Speaker 1>that our competition does not have at this point, so

0:02:21.560 --> 0:02:26.240
<v Speaker 1>I'm incredibly grateful for that. Now you talked about restrictions.

0:02:26.560 --> 0:02:28.880
<v Speaker 1>I think there's a lot of drugs that have restrictions,

0:02:28.919 --> 0:02:32.680
<v Speaker 1>including our own diabetes version of this called Rebulses, where

0:02:32.720 --> 0:02:35.040
<v Speaker 1>we have one and a half million patients on the

0:02:35.120 --> 0:02:39.080
<v Speaker 1>product and not complaining whatsoever about that restrictions. We have

0:02:39.160 --> 0:02:42.399
<v Speaker 1>this simple saying of sip and go. So I'm very

0:02:42.440 --> 0:02:45.120
<v Speaker 1>thankful that we basically have been able to prove that

0:02:45.200 --> 0:02:48.960
<v Speaker 1>on the market with Rebulses, and I'm very optimistic that

0:02:49.040 --> 0:02:50.360
<v Speaker 1>vigovi pill will show the same.

0:02:50.560 --> 0:02:53.440
<v Speaker 2>Let's talk a little bit about production of the pill,

0:02:53.520 --> 0:02:56.200
<v Speaker 2>because you think about the amount that you need of

0:02:56.240 --> 0:02:59.560
<v Speaker 2>the drug ingredient for the pill versus the shots. How

0:02:59.639 --> 0:03:03.000
<v Speaker 2>profit is it to make and produce the pills versus

0:03:03.040 --> 0:03:03.560
<v Speaker 2>the shots.

0:03:03.680 --> 0:03:06.239
<v Speaker 1>Well, if you could not make any financial gains or

0:03:06.280 --> 0:03:08.120
<v Speaker 1>profits out of it, then we probably would not have

0:03:08.200 --> 0:03:11.360
<v Speaker 1>launched it. So we have made a couple of things

0:03:11.480 --> 0:03:14.560
<v Speaker 1>very clear. Again, it comes back to the skepticism that

0:03:15.320 --> 0:03:21.120
<v Speaker 1>growing their peptide route orally is the wrong one because

0:03:21.160 --> 0:03:23.400
<v Speaker 1>no one else has done it. That people first and

0:03:23.480 --> 0:03:26.800
<v Speaker 1>foremost started telling us it's not scientifically possible. When we

0:03:26.880 --> 0:03:29.440
<v Speaker 1>prove that right, then they started focusing well can you

0:03:29.520 --> 0:03:31.880
<v Speaker 1>produce enough of it? And is it profitable? And we

0:03:32.120 --> 0:03:35.160
<v Speaker 1>basically tell people that we have produced more than enough

0:03:35.160 --> 0:03:38.120
<v Speaker 1>of it, that's why we're launching it, and that we

0:03:38.200 --> 0:03:40.280
<v Speaker 1>are actually going to make a decent business out of this.

0:03:40.560 --> 0:03:44.320
<v Speaker 1>So I'm very optimistic about this pill as we go forward.

0:03:44.400 --> 0:03:47.520
<v Speaker 1>And again the single biggest difference, and people have not

0:03:47.640 --> 0:03:52.080
<v Speaker 1>understood that this is not a chemical entity, small molecule

0:03:52.520 --> 0:03:55.960
<v Speaker 1>as almost all pills are. Because of that, you have

0:03:56.040 --> 0:04:01.200
<v Speaker 1>an incredibly potent, effective pill at hand which we have

0:04:02.080 --> 0:04:05.360
<v Speaker 1>uniquely learned how to scale it and of course make

0:04:05.400 --> 0:04:06.720
<v Speaker 1>a decent business out of it.

0:04:06.960 --> 0:04:09.520
<v Speaker 2>So let's talk a little bit about pricing as well,

0:04:09.560 --> 0:04:12.200
<v Speaker 2>because you were one of several drug companies that signed

0:04:12.240 --> 0:04:15.200
<v Speaker 2>pricing deals with the White House at the end of

0:04:15.320 --> 0:04:18.640
<v Speaker 2>last year. So you think about medicare you think about Medicaid?

0:04:18.920 --> 0:04:22.080
<v Speaker 2>How much of your obesity business do you think could

0:04:22.120 --> 0:04:24.840
<v Speaker 2>actually come from those two avenues.

0:04:24.760 --> 0:04:27.680
<v Speaker 1>What we have seen recently. Of course, the Lion's share

0:04:27.680 --> 0:04:30.240
<v Speaker 1>of the business still is through the insured channels, and

0:04:30.279 --> 0:04:32.440
<v Speaker 1>I think for a long time it probably remains that.

0:04:33.160 --> 0:04:37.040
<v Speaker 1>But you have also seen that unfortunately through the insurance channels,

0:04:37.080 --> 0:04:40.640
<v Speaker 1>even though the sheer number of people that have insurances

0:04:40.880 --> 0:04:43.440
<v Speaker 1>are large, So fifty five million people are insured with

0:04:43.480 --> 0:04:46.960
<v Speaker 1>our Vigovi product. Because of all the restrictions that are

0:04:47.000 --> 0:04:52.240
<v Speaker 1>put upon them, the pre authorizations and basically a lot

0:04:52.279 --> 0:04:55.200
<v Speaker 1>of questionnaires that they need to fill, many of these

0:04:55.240 --> 0:04:59.120
<v Speaker 1>patients preferred to go through the cash channels and pay

0:05:00.320 --> 0:05:04.080
<v Speaker 1>amount of money albeit a bit larger than their copy,

0:05:04.800 --> 0:05:07.240
<v Speaker 1>but source the product from the cash channel. So we

0:05:07.320 --> 0:05:09.320
<v Speaker 1>have seen both for us as well as our competition,

0:05:09.600 --> 0:05:12.560
<v Speaker 1>that the growth recently has been through the cash channels.

0:05:12.800 --> 0:05:15.599
<v Speaker 1>We will work very well with both of these channels.

0:05:15.640 --> 0:05:18.840
<v Speaker 1>We will continue, of course working incredibly tight with our

0:05:18.880 --> 0:05:23.560
<v Speaker 1>partners in the in short section, but continue to develop

0:05:24.880 --> 0:05:27.039
<v Speaker 1>the cash channels as we do think that this is

0:05:27.040 --> 0:05:28.240
<v Speaker 1>the future in many ways.

0:05:28.360 --> 0:05:30.200
<v Speaker 2>That's really interesting when you talk about, you know, the

0:05:30.240 --> 0:05:32.800
<v Speaker 2>growth coming from the cash channel, are you able to

0:05:32.920 --> 0:05:34.880
<v Speaker 2>quantify that, you know the type of numbers that you

0:05:34.920 --> 0:05:35.400
<v Speaker 2>are seeing.

0:05:35.680 --> 0:05:39.680
<v Speaker 1>Well, last year we had basically had ten percent of

0:05:39.680 --> 0:05:42.599
<v Speaker 1>our sales coming through the cash channels, and that we

0:05:43.000 --> 0:05:45.560
<v Speaker 1>publicly said it's not good enough for our competition. I

0:05:45.640 --> 0:05:48.040
<v Speaker 1>believe the number was around thirty percent or so, So

0:05:48.080 --> 0:05:50.960
<v Speaker 1>we have set ourselves the goal to increase the number

0:05:51.200 --> 0:05:55.880
<v Speaker 1>and go forward. But we also recognize that many patients

0:05:56.160 --> 0:05:58.400
<v Speaker 1>don't necessarily want to come to your own website. We

0:05:58.400 --> 0:06:01.800
<v Speaker 1>have a website called Noble Care Pharmacy dot com, which

0:06:01.839 --> 0:06:03.560
<v Speaker 1>is good and now we have revamped it and I'm

0:06:03.640 --> 0:06:06.040
<v Speaker 1>very proud of it. But the truth is that some

0:06:06.040 --> 0:06:08.960
<v Speaker 1>people actually like to source the product from Row, from

0:06:09.080 --> 0:06:14.159
<v Speaker 1>Life MD, from Weight Watchers, from Amazon Pharmacy, and we

0:06:14.200 --> 0:06:17.080
<v Speaker 1>should be able to basically allow them rather than try

0:06:17.120 --> 0:06:19.719
<v Speaker 1>to force them to only come through our own channel.

0:06:19.839 --> 0:06:21.920
<v Speaker 1>So what you have seen from our company over the

0:06:22.000 --> 0:06:27.400
<v Speaker 1>last five six months is major number of partnerships with

0:06:27.560 --> 0:06:30.520
<v Speaker 1>all of these players so that patients don't need to

0:06:30.560 --> 0:06:33.320
<v Speaker 1>move away from wherever they are, will join them and

0:06:33.360 --> 0:06:34.560
<v Speaker 1>meet them where they are.

0:06:34.839 --> 0:06:38.320
<v Speaker 2>Yeah, that's fascinating, especially when it comes to the telehealth platforms.

0:06:38.400 --> 0:06:41.400
<v Speaker 2>It feels like that's becoming ubiquitous in American life. I

0:06:41.440 --> 0:06:43.359
<v Speaker 2>do want to talk a little bit about, you know,

0:06:43.440 --> 0:06:47.080
<v Speaker 2>potential catalysts from here. Obviously the pill in that approval

0:06:47.200 --> 0:06:49.679
<v Speaker 2>was a big one, but you think about the readout

0:06:49.680 --> 0:06:52.280
<v Speaker 2>that you're seeing when it comes to redefine for that

0:06:52.440 --> 0:06:56.040
<v Speaker 2>is cagrisama versus set bound. My understanding that's due in

0:06:56.080 --> 0:06:59.480
<v Speaker 2>the first quarter. What's your consonance level as you're heading

0:06:59.480 --> 0:06:59.800
<v Speaker 2>into that.

0:07:00.360 --> 0:07:02.880
<v Speaker 1>We have we have two trials looking forward to. There's

0:07:02.880 --> 0:07:06.760
<v Speaker 1>redefined four and Redefine eleven. I would say. On redefined four,

0:07:07.200 --> 0:07:10.560
<v Speaker 1>we are trying to get non inferiority, so so that's

0:07:10.680 --> 0:07:15.080
<v Speaker 1>really important to to to speak to. On redefined eleven,

0:07:15.120 --> 0:07:18.520
<v Speaker 1>we have re changed our methodology and redesigned the trial

0:07:18.880 --> 0:07:23.920
<v Speaker 1>a bit differently. It's here with American patients only, and

0:07:24.120 --> 0:07:27.400
<v Speaker 1>we are asking the patients to tight trate, albeit at

0:07:27.400 --> 0:07:30.560
<v Speaker 1>their own pace. So so I'm a little bit looking

0:07:30.600 --> 0:07:33.840
<v Speaker 1>more forward to redefine eleven, I would say. But but

0:07:34.000 --> 0:07:36.400
<v Speaker 1>on both of those we will once again prove that

0:07:36.520 --> 0:07:41.320
<v Speaker 1>Tagrick Semma is the next generation of the product, and

0:07:41.160 --> 0:07:45.000
<v Speaker 1>and it's going to have not only a very decent efficacy,

0:07:45.920 --> 0:07:48.800
<v Speaker 1>much more than what we see in the market currently today,

0:07:49.360 --> 0:07:53.040
<v Speaker 1>but also with a very reasonable tolerability, which I think

0:07:53.440 --> 0:07:57.280
<v Speaker 1>comes from the amline molecule that really has proven to

0:07:57.320 --> 0:08:00.880
<v Speaker 1>be a fantastic molecule in weight management when especially comes

0:08:00.880 --> 0:08:01.840
<v Speaker 1>to tolerability.

0:08:02.000 --> 0:08:05.120
<v Speaker 2>So redefine four, but especially redefine eleven, we'll be keeping

0:08:05.120 --> 0:08:07.560
<v Speaker 2>an eye out for that. I do have to ask

0:08:07.600 --> 0:08:09.640
<v Speaker 2>you a little bit when it comes to the politics

0:08:09.920 --> 0:08:12.440
<v Speaker 2>of it all. We know the President Donald Trump isn't

0:08:12.440 --> 0:08:14.560
<v Speaker 2>a feud if you want to call it, with Denmark

0:08:14.600 --> 0:08:18.040
<v Speaker 2>over Greenland. Of course, you are based in Denmark. How

0:08:18.080 --> 0:08:20.440
<v Speaker 2>do you make sure that what's going on at the

0:08:20.440 --> 0:08:24.560
<v Speaker 2>government level doesn't impact your own dealings with the Trump administration?

0:08:24.640 --> 0:08:26.840
<v Speaker 1>So I learned a long time ago that one of

0:08:26.920 --> 0:08:30.480
<v Speaker 1>the benefits of working in the pharmaceutical industry is you

0:08:30.520 --> 0:08:35.079
<v Speaker 1>could basically tell both sides of the of the of

0:08:35.400 --> 0:08:39.760
<v Speaker 1>the politics that I'm here for the patients. My job

0:08:39.920 --> 0:08:42.079
<v Speaker 1>is to put the patients at the center of everything

0:08:42.120 --> 0:08:47.280
<v Speaker 1>that I do, and patients are my politics. And interesting enough,

0:08:47.320 --> 0:08:49.400
<v Speaker 1>it doesn't matter if you're the right side or the

0:08:49.480 --> 0:08:53.840
<v Speaker 1>left side of the political spectrum. You understand that because

0:08:54.240 --> 0:08:59.760
<v Speaker 1>both sides often agree that improving health especially at scales

0:09:00.200 --> 0:09:02.800
<v Speaker 1>like we do, is the most important thing. So I

0:09:02.840 --> 0:09:05.960
<v Speaker 1>will leave the politics to the politicians, and my job

0:09:06.000 --> 0:09:10.760
<v Speaker 1>is to really focus around expanding access to healthcare, which

0:09:10.800 --> 0:09:12.200
<v Speaker 1>my company is synonymous for.

0:09:12.559 --> 0:09:15.240
<v Speaker 2>Patients are your politics. I like that. I do want

0:09:15.240 --> 0:09:17.400
<v Speaker 2>to talk a little bit about AI. We are sitting

0:09:17.400 --> 0:09:21.320
<v Speaker 2>here having this conversation in San Francisco, and AI and

0:09:21.360 --> 0:09:23.640
<v Speaker 2>its potential when it comes to the health industry has

0:09:23.640 --> 0:09:26.760
<v Speaker 2>definitely emerged as a theme. You think about Eli Lilly,

0:09:26.800 --> 0:09:29.720
<v Speaker 2>the partnerships that they've signed with in Video, the news

0:09:29.720 --> 0:09:32.120
<v Speaker 2>from this conference that in Video will invest a billion

0:09:32.160 --> 0:09:35.600
<v Speaker 2>dollars in developing a lab with Eli Lilly. How are

0:09:35.640 --> 0:09:38.320
<v Speaker 2>you thinking about AI when it comes to your business

0:09:38.400 --> 0:09:42.000
<v Speaker 2>and could you anticipate Novo signing some sort of similar

0:09:42.040 --> 0:09:44.040
<v Speaker 2>partnership with one of these AI companies.

0:09:44.200 --> 0:09:46.439
<v Speaker 1>I would say that when you think about technology as

0:09:46.440 --> 0:09:49.960
<v Speaker 1>a whole and pharmaceuticals, the pharma industry has been a

0:09:49.960 --> 0:09:55.400
<v Speaker 1>bit conservative adapting technology more much less than some of

0:09:55.400 --> 0:09:58.760
<v Speaker 1>the other, of course industries that you see predominantly, maybe

0:09:58.760 --> 0:10:03.440
<v Speaker 1>because as humans we have shied away about sharing our

0:10:03.840 --> 0:10:07.160
<v Speaker 1>health related data as much as we talk about where

0:10:07.280 --> 0:10:10.559
<v Speaker 1>we ate and where we walked on Instagram or Facebook,

0:10:11.600 --> 0:10:14.360
<v Speaker 1>coming to discussing our health issues has been a little

0:10:14.400 --> 0:10:19.040
<v Speaker 1>bit more reserved. That is changing. I think an AI

0:10:19.240 --> 0:10:22.440
<v Speaker 1>is really becoming an interesting topic and I have no

0:10:22.559 --> 0:10:25.800
<v Speaker 1>doubt AI will answer many of the questions we have

0:10:25.920 --> 0:10:29.520
<v Speaker 1>not been able to answer. If you think about our industry,

0:10:29.840 --> 0:10:34.439
<v Speaker 1>it's a lot about trials and errors and really trying

0:10:34.480 --> 0:10:37.240
<v Speaker 1>to figure out will this work or not. With the

0:10:37.240 --> 0:10:41.880
<v Speaker 1>help of AI, I think those answers will be addressed

0:10:42.040 --> 0:10:44.920
<v Speaker 1>much differently than we have been able to do without them.

0:10:45.120 --> 0:10:50.079
<v Speaker 1>So I think from discovery to research, AI is going

0:10:50.120 --> 0:10:54.040
<v Speaker 1>to play a major role in understanding science and bringing

0:10:54.360 --> 0:10:57.199
<v Speaker 1>molecules and drugs faster to markets. But also when you

0:10:57.240 --> 0:11:00.400
<v Speaker 1>get into the regulatory front and being able to file

0:11:00.559 --> 0:11:03.320
<v Speaker 1>for approvals, I think you can also shorten the time.

0:11:03.800 --> 0:11:07.760
<v Speaker 1>So my hope is in years to come you will

0:11:07.800 --> 0:11:11.640
<v Speaker 1>see from the onset of an idea from a scientist

0:11:12.120 --> 0:11:15.080
<v Speaker 1>to a placement of a product in a pharmacy, you

0:11:15.120 --> 0:11:18.480
<v Speaker 1>will see a shorter time horizon than today's ten to

0:11:18.559 --> 0:11:21.400
<v Speaker 1>fifteen years, which ultimately will benefit the patience